SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-217549
Filing Date
2021-07-16
Accepted
2021-07-16 17:11:08
Documents
13
Period of Report
2021-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d139964d8k.htm   iXBRL 8-K 24207
2 EX-10.1 d139964dex101.htm EX-10.1 264935
  Complete submission text file 0001193125-21-217549.txt   467326

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20210715.xsd EX-101.SCH 2915
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20210715_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20210715_pre.xml EX-101.PRE 10968
6 EXTRACTED XBRL INSTANCE DOCUMENT d139964d8k_htm.xml XML 3304
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 211096171
SIC: 2834 Pharmaceutical Preparations